BIM-51077, a dipeptidyl peptidase-IV-resistant glucagon-like peptide-1 analog.
F Hoffmann-La Roche Ltd, Teijin Ltd and Chugai Pharmaceutical Co Ltd, under license from Ipsen, are developing the glucagon-like peptide 1 analog BIM-51077, for the potential treatment of type 2 diabetes. Phase II clinical trials are underway, including a phase II trial evaluating a slow release formulation.